Intravenous tezosentan and vardenafil attenuate acute hypoxic pulmonary hypertension

High Altitude Medicine and Biology

Volumn 9, Issue 3, 2008, Pages 223-227

  Geiger, Ralf ^a   Treml, Benedikt ^a   Kleinsasser, Axel ^a   Neu, Nikolaus ^a   Fischer, Victoria ^a   Stein, Joerg I ^a   Loeckinger, Alexander ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Hypoxia; Pulmonary hypertension; Tezosentan; Vardenafil

Indexed keywords

TEZOSENTAN; VARDENAFIL;

ACUTE DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HEART INDEX; HYPOXIA; HYPOXIC LUNG VASOCONSTRICTION; LUNG ALVEOLUS OXYGEN TENSION; LUNG ARTERY PRESSURE; LUNG GAS EXCHANGE; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; MALE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SWINE; VASODILATATION;

ANIMALS; ANOXIA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMODYNAMICS; HYPERTENSION, PULMONARY; IMIDAZOLES; INJECTIONS, INTRAVENOUS; MALE; PIPERAZINES; PULMONARY GAS EXCHANGE; PYRIDINES; RANDOM ALLOCATION; SULFONES; SWINE; TETRAZOLES; TRIAZINES; VASODILATOR AGENTS;

EID: 52449089197     PISSN: 15270297     EISSN: None     Source Type: Journal    
DOI: 10.1089/ham.2008.1024     Document Type: Article

References (32)

1. Ambalavanan N, Bulger A., Murphy-Ullrich J., Oparil S., and Chen Y.F. (2005). Endothelin-A receptor blockade prevents and partially reverses neonatal hypoxic pulmonary vascular remodeling. Pediatr. Res. 57:631-636.
2. Bardou M., Goirand F., Marchand S., Rouget C., Devillier P., Dumas J.P., Morcillo E.J., Rochette L., and Dumas M. (2001). Hypoxic vasoconstriction of rat main pulmonary artery: role of endogenous nitric oxide, potassium channels, and phosphodiesterase inhibition. J. Cardiovasc. Pharmacol. 38:325-334.
3. Brimioulle S., LeJeune P., and Naeije R. (1996). Effects of hypoxic pulmonary vasoconstriction on pulmonary gas exchange. J. Appl. Physiol. 81:1535-1543.
4. Brody S. and Kibler H.H. (1944). Resting energy metabolism and pulmonary ventilation in growing swine. Missouri Univ. Agr. Expt. Sta. Res. Bul. l 380:2-20.
5. Corbin J.D. and Francis S.H. (2002). Pharmacology of phosphodiesterase-5 inhibitors. Int. J. Clin. Pract. 56:453-459.
6. Corbin J.D., Beasley A., Blount M.A., and Francis S.H. (2004). Vardenafil: structural basis for higher potency over sildenafil in inhibiting cGMP-specific phoshodiesterase-5 (PDE-5). Neurochem. Int. 45:859-863.
7. Faoro V., Lamotte M., Deboeck G., Pavelescu A., Huez S., Guenard H., Martinot J.B., and Naeije R. (2007). Effects of sildenafil on exercise capacity in hypoxic normal subjects. High Alt. Med. Biol. 8:155-163.
8. Fitzgerald R.K., Oishi P., Ovadia B., Ross G.A., Reinhartz O., Johengen M.J., and Fineman J.R. (2004). Tezosentan, a combined parenteral endothelin receptor antagonist, produces pulmonary vasodilation in lambs with acute and chronic pulmonary hypertension. Pediatr. Crit. Care Med. 571-577.
9. Geiger R., Pajk W., Neu N., Maier S., Kleinsasser A., Fratz S., Navarro-Psihas S., Fischer V., Treml B., and Loeckinger A. (2006). Tezosentan decreases pulmonary artery pressure and improves survival rate in an animal model of meconium aspiration. Pediatr. Res. 59:147-150.
10. Geiger R., Kleinsasser A., Meier S., Neu N., Pajk W., Fischer V., Treml B., Stein J.I., and Loeckinger A. (2008). Intraveous tezosentan improves gas exchange and hemodynamics in acute lung injury secondary to meconium aspiration. Intensive Care Med. 34:368-376.
11. Ghofrani H.A., Voswinckel R., Reichenberger F., Olschewski H., Haredza P., Karadas B., Schermuly R.T., Weissmann N., Seeger W., and Grimminger F. (2004). Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension. J. Am. Coll. Cardiol. 44:1488-1496.
12. Ghofrani H.A., Reichenberger F., Kohstall M.G., Mrosek E.H., Seeger T., Olschewski H., Seeger W., and Grimminger F. (2004). Sildenafil increased exercise capacity during hypoxia at low altitudes and at Mount Everest base camp. A randomized, double-blind, placebocontrolled crossover trial. Ann. Intern. Med. 41:169-177.
13. Holm P., Liska J., Clozel M., and Franco-Cereceda A. (1996). The endothelin antagonist bosentan: hemodymamic effects during normoxia and hypoxic pulmonary hypertension in pigs. J. Thorac. Cardiovasc. Surg. 12:890-897.
14. Holm P. (1997). Endothelin in the pulmonary circulation with special reference to hypoxic pulmonary vasoconstriction. Scand. Cardiovasc. J. Suppl. 46:1-40.
15. Huez S., Faoro V., VachiÈry J.L., Unger P., Martinot J.B., and Naeije R. (2007) Images in cardiovascular medicine. High-altitude-induced right-heart failure. Circulation 6;115:e308-e309
16. Humbert M., Sitbon O., and Simonneau G. (2004). Treatment of pulmonary arterial hypertension. N. Engl. J. Med. 351:1425-1436.
17. Lewis G.D., Lachmann J., Camuso J., Lepore J.J., Shin J., Martinovic M.E., Systrom D.M., Bloch K.D., and Semigran M.J. (2007). Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation 115:59-66.
18. Li H., Elton T.S., Chen Y.F., and Oparil S. (1994). Increased endothelin receptor gene expression in hypoxic rat lung. Am. J. Physiol. 266:L553-560.
19. Maggiorini M., Brunner-La Rocca H.P., Peth S., Fischler M., Böhm T., Bernheim A., Kiencke S., Bloch K.E., Dehnert C., Naeije R., Lehmann T., Bartsch P., and Mairbaurl H. (2006). Both Tadalafil and dexamethasone may reduce the incidence of High-Altitude Pulmonary Edema. Ann. Intern. Med. 145:497-506.
20. McLean M.R., Johnston E.D., Mcculloch K.M., Pooley L., Houslay M.D., and Sweeney G. (1997). Phosphodiesterase isoforms in the pulmonary arterial circulation of the rat: changes in pulmonary hypertension. J. Pharmacol. Exp. Ther. 283:619-624.
21. Michel R.P., Langleben D., and Depuis J. (2003). The endothelin system in pulmonary hypertension. Can. J. Physiol. Pharmacol. 81:542-554.
22. Moudgil R., Michelakis E.D., and Archer S.L. (2005). Hypoxic pulmonary vasoconstriction. J. Appl. Physiol. 98: 390-403.
23. Naeije R. (2004). Pulmonary vascular function. In: Pulmonary Circulation: Diseases and Their Treatment, edited by A.J. Peacock and J.R. Rubin, Arnold, London, pp. 1-13.
24. Oka M., Homma N., Taraseviciene-Stewart L., Morris K.G., Kraskauskas D., Burns N.,Voelkel N.F., and McMurtry I.F. (2007). Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats. Circ. Res. 100:923-929.
25. Pauvert O., Bonnet S., Rousseau E., Marthan R., and Savineau J.P. (2004). Sildenafil alters calcium signaling and vascular tone in pulmonary arteries from chronically hypoxic rats. Am J Physiol. Lung Cell. Mol. Physiol. 287:L577-L583.
26. Scherrer U., Vollenweider L., Delabays A., Savcic M., Eichenberger U., Kleger G.R., Fikrle A., Ballmer P.E., Nicod P., and Bartsch P. (1996). Inhaled nitric oxide for high-altitude pulmonary edema. N. Engl. J. Med. 334:624-629.
27. Thomas H.M. 3rd, and Garrett R.C. (1982). Strength of hypoxic vasoconstriction determines shunt fraction in dogs with atelectasis. J. Appl. Physiol. 53:44-51.
28. Tsai B.M., Turrentine M.W., Sheridan B.C., Wang M., Fiore A.C., Brown J.W., and Meldrum D.R. (2006). Differential effects of phosphodiesterase-5 inhibitors on hypoxic pulmonary vasoconstriction and pulmonary artery cytokine expression. Ann. Thorac. Surg. 81:272-278.
29. Vanlersberghe C., and Camu F. (2008). Propofol. Handb. Exp. Pharmacol. 182:227-252.
30. Wang L., Zhu du M., Su X., Bai C.X., Ware L.B., and Matthay M.A. (2004). Acute cardiopulmonary effects of a dual-endothelin receptor antagonist on oleic acid-induced pulmonary arterial hypertension in dogs. Exp. Lung Res. 30:31-42.
31. Weitzenblum E., and Chaouat A. (2004). Pulmonary hypertension due to chronic hypoxic lung disease. In: Peacock AJ, Rubin JR (eds), Pulmonary circulation: Diseases and their treatment, London: Arnold; p. 1-13.
32. Yu A.Y., Frid M.G., Shimoda L.A., Wiener C.M., Stenmark K., and Semenza G.L. (1998). Temporal, spatial, and oxygen-regulated expression of hypoxia-inducible factor-1 in the lung. Am. J. Physiol. 275:L818-826.